1998
DOI: 10.1136/thx.53.7.536
|View full text |Cite
|
Sign up to set email alerts
|

Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998

Abstract: (Thorax 1998;53:536-548)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
8
0

Year Published

2002
2002
2016
2016

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 406 publications
(10 citation statements)
references
References 69 publications
0
8
0
Order By: Relevance
“…Differentiating between TB DILI, ART-induced DILI and immune reconstitution inflammatory syndrome (IRIS) is challenging. [10][11][12] When comparing TB DILI patients on ART v. not on ART, we observed some interesting differences. Patients on ART tended to have a significantly longer duration of TBT at DILI diagnosis, lower ALT at DILI diagnosis, longer treatment interruption until rechallenge of TBT, smaller serial changes in ALT, and higher odds of receiving a modified TBT regimen.…”
Section: Discussionmentioning
confidence: 89%
“…Differentiating between TB DILI, ART-induced DILI and immune reconstitution inflammatory syndrome (IRIS) is challenging. [10][11][12] When comparing TB DILI patients on ART v. not on ART, we observed some interesting differences. Patients on ART tended to have a significantly longer duration of TBT at DILI diagnosis, lower ALT at DILI diagnosis, longer treatment interruption until rechallenge of TBT, smaller serial changes in ALT, and higher odds of receiving a modified TBT regimen.…”
Section: Discussionmentioning
confidence: 89%
“…National guidelines suggest treatment duration of 6 months, except in severe cases, where 9-12 months treatment regimens are applied, as also recommended by WHO [17]. This is in contrast to the recommendations applied in the United Kingdom and the United States, where all TBM patients are treated for 9-12 months [18,19]. A high proportion of the patients were treated with adjuvant prednisolone treatment; this is a well-established component of TBM treatment and has been shown to significantly reduce mortality rates [20].…”
Section: Discussionmentioning
confidence: 99%
“…The diagnosis of rifampin monoresistance is also critical because this automatically invalidates the use of short-course chemotherapy ( 25 ). Of the 59 correctly identified rifampin-resistant MTBC isolates, 11 were rifampin monoresistant.…”
Section: Discussionmentioning
confidence: 99%